PF-06439015

Details

Stereochemistry	ABSOLUTE
Molecular Formula	C22H23FN6O3S
Molecular Weight	470.52
Optical Activity	UNSPECIFIED
Defined Stereocenters	2 / 2
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

C[C@@H](OC1=CC(=CN=C1N)C2=C(C)N=C(S2)[C@](C)(O)CO)C3=CC(F)=CC=C3N4N=CC=N4

InChI

InChIKey=DIXMBHMNEHPFCX-MCMMXHMISA-N

InChI=1S/C22H23FN6O3S/c1-12-19(33-21(28-12)22(3,31)11-30)14-8-18(20(24)25-10-14)32-13(2)16-9-15(23)4-5-17(16)29-26-6-7-27-29/h4-10,13,30-31H,11H2,1-3H3,(H2,24,25)/t13-,22-/m1/s1

HIDE SMILES / InChI

Molecular Formula	C22H23FN6O3S
Molecular Weight	470.52
Charge	0
Count

Stereochemistry	ABSOLUTE
Additional Stereochemistry	No
Defined Stereocenters	2 / 2
E/Z Centers	0
Optical Activity	UNSPECIFIED

Description
Sources: https://www.ncbi.nlm.nih.gov/pubmed/24432909

PF-06439015 is a potent and selective inihibitor that overcomes clinical ALK (receptor tyrosine kinase anaplastic lymphoma kinase) mutations resistant to Crizotinib. PF-06439015 is potent across a broad panel of ALK mutant cell lines with an IC50 of 6.6 nM for tumor growth inhibition in a crizotinib-resistant cell line (H3122-L1196M).

Originator

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
ALK tyrosine kinase receptor 24 Target ID: CHEMBL4247 Sources: https://www.ncbi.nlm.nih.gov/pubmed/24432909	Inhibitor 8504		0.8 nM [IC50]
Proto-oncogene tyrosine-protein kinase ROS 5 Target ID: CHEMBL5568 Sources: https://www.ncbi.nlm.nih.gov/pubmed/24432909	Inhibitor 8504		0.02 nM [Ki]

Conditions

Condition	Modality	Targets	Highest Phase	Product
Non-small cell lung cancer 211 Sources: https://www.ncbi.nlm.nih.gov/pubmed/24432909	Primary		Preclinical	Unknown Approved Use Unknown

PubMed

Title	Date	PubMed
Design of potent and selective inhibitors to overcome clinical anaplastic lymphoma kinase mutations resistant to crizotinib.	2014-02-27	24432909

Sample Use Guides

In Vivo Use Guide

Mouse tumor xenograft study: PF-06439015 showed tumor stasis (100% TGI) at both the 30 mg/kg q.d. and 15 mg/kg b.i.d. doses. The highest dose (50 mg/kg b.i.d) showed significant tumor growth regression (56%) on day 27.

Route of Administration: Oral

In Vitro Use Guide

PF-06439015 inhibited crizotinib-resistant cell line (H3122-L1196M) tumor growth with IC50 6.6 nM.

Substance Class	Chemical Created by `admin` on `Mon Mar 31 22:34:42 GMT 2025` Edited by `admin` on `Mon Mar 31 22:34:42 GMT 2025`
Record UNII	76PND635L1
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

(2R)-2-(5-(6-AMINO-5-((1R)-1-(5-FLUORO-2-(2H-1,2,3-TRIAZOL-2-YL)PHENYL)ETHOXY)-3-PYRIDINYL)-4-METHYL-2-THIAZOLYL)-1,2-PROPANEDIOL

Preferred Name

English

PF-06439015

Common Name

English

1,2-PROPANEDIOL, 2-(5-(6-AMINO-5-((1R)-1-(5-FLUORO-2-(2H-1,2,3-TRIAZOL-2-YL)PHENYL)ETHOXY)-3-PYRIDINYL)-4-METHYL-2-THIAZOLYL)-, (2R)-

Systematic Name

English

Code System Code Type Description

CAS

1549629-82-4

Created by admin on Mon Mar 31 22:34:42 GMT 2025 , Edited by admin on Mon Mar 31 22:34:42 GMT 2025

PRIMARY

PUBCHEM

72710568

Created by admin on Mon Mar 31 22:34:42 GMT 2025 , Edited by admin on Mon Mar 31 22:34:42 GMT 2025

PRIMARY

FDA UNII

76PND635L1

Created by admin on Mon Mar 31 22:34:42 GMT 2025 , Edited by admin on Mon Mar 31 22:34:42 GMT 2025

PRIMARY

Related Record Type Details


					6P6Y82PIL1

LEUKOCYTE TYROSINE KINASE RECEPTOR

TARGET -> INHIBITOR


					AA5QJ7X54B

ANAPLASTIC LYMPHOMA KINASE L1196M

TARGET -> INHIBITOR

Qualification:

Ki

Amount:


					AA5QJ7X54B

ANAPLASTIC LYMPHOMA KINASE L1196M

TARGET -> INHIBITOR

Comments:

cellular assay

Qualification:

IC50

Amount:

Related Record Type Details


					76PND635L1

PF-06439015

ACTIVE MOIETY

Details

SMILES

InChI

DescriptionSources: https://www.ncbi.nlm.nih.gov/pubmed/24432909

Originator

Approval Year

Targets

Conditions

Approved Use

PubMed

Sample Use Guides

Description
Sources: https://www.ncbi.nlm.nih.gov/pubmed/24432909